- Home
- FOXF vs ATXS Comparison
FOXF vs ATXS Comparison
Compare FOXF & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOXF | ATXS |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 732.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FOXF | ATXS |
|---|---|---|
| Price | $17.00 | $13.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $33.00 | $24.33 |
| AVG Volume (30 Days) | 950.8K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,459,086,000.00 | $706,000.00 |
| Revenue This Year | $6.82 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $13.08 | $3.56 |
| 52 Week High | $31.18 | $13.29 |
Technical Indicators
Market Signals| Indicator | FOXF | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 65.77 |
| Support Level | $17.41 | $12.64 |
| Resistance Level | $17.86 | $13.03 |
| Average True Range (ATR) | 0.53 | 0.20 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 40.82 | 95.00 |
Price Performance
Historical ComparisonAbout FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.